Personalized therapies in pediatric inflammatory and autoimmune diseases

Gabriele Stocco, Sara de Iudicibus, Raffaella Franca, Riccardo Addobbati, Giuliana Decorti

Research output: Contribution to journalArticle

Abstract

Pediatric inflammatory and autoimmune diseases are a wide array of systemic or organ-specific conditions, characterized by an exaggerated immune reactivity, which generally occurs in immunogenetically predisposed children. Among the most important ones, in terms of their diffusion and morbidity in the population worldwide, pediatric inflammatory bowel disease (IBD) and juvenile rheumatoid arthritis (JRA) have to be considered. The aim of personalized therapy is to give to each patient the most appropriate drug and dose regimen, in order to maximize treatment response and reduce the risk of adverse events. In general, several therapeutic options exist for pediatric inflammatory and autoimmune conditions, therefore the perspective of pharmacological tools that allow identification of patients with increased risk of treatment issues related to a particular medication, in terms of lack of efficacy or increased probability of adverse events, is particularly desirable and promising. The present review will be focused on the personalized therapy approaches already available or in development for pediatric patients with IBD or JRA, comprising pharmacokinetic, pharmacodynamic and pharmacogenetic assays.

Original languageEnglish
Pages (from-to)5766-5775
Number of pages10
JournalCurrent Pharmaceutical Design
Volume18
Issue number35
DOIs
Publication statusPublished - 2012

Fingerprint

Autoimmune Diseases
Pediatrics
Juvenile Arthritis
Inflammatory Bowel Diseases
Therapeutics
Pharmacogenetics
Pharmacokinetics
Pharmacology
Morbidity
Pharmaceutical Preparations
Population

Keywords

  • Juvenile rheumatoid arthritis
  • Pediatric inflammatory bowel disease
  • Personalized therapy
  • Pharmacodynamics
  • Pharmacogenetics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Personalized therapies in pediatric inflammatory and autoimmune diseases. / Stocco, Gabriele; de Iudicibus, Sara; Franca, Raffaella; Addobbati, Riccardo; Decorti, Giuliana.

In: Current Pharmaceutical Design, Vol. 18, No. 35, 2012, p. 5766-5775.

Research output: Contribution to journalArticle

Stocco, Gabriele ; de Iudicibus, Sara ; Franca, Raffaella ; Addobbati, Riccardo ; Decorti, Giuliana. / Personalized therapies in pediatric inflammatory and autoimmune diseases. In: Current Pharmaceutical Design. 2012 ; Vol. 18, No. 35. pp. 5766-5775.
@article{f7c43e4004854aafbd9bf69dbe0bc7de,
title = "Personalized therapies in pediatric inflammatory and autoimmune diseases",
abstract = "Pediatric inflammatory and autoimmune diseases are a wide array of systemic or organ-specific conditions, characterized by an exaggerated immune reactivity, which generally occurs in immunogenetically predisposed children. Among the most important ones, in terms of their diffusion and morbidity in the population worldwide, pediatric inflammatory bowel disease (IBD) and juvenile rheumatoid arthritis (JRA) have to be considered. The aim of personalized therapy is to give to each patient the most appropriate drug and dose regimen, in order to maximize treatment response and reduce the risk of adverse events. In general, several therapeutic options exist for pediatric inflammatory and autoimmune conditions, therefore the perspective of pharmacological tools that allow identification of patients with increased risk of treatment issues related to a particular medication, in terms of lack of efficacy or increased probability of adverse events, is particularly desirable and promising. The present review will be focused on the personalized therapy approaches already available or in development for pediatric patients with IBD or JRA, comprising pharmacokinetic, pharmacodynamic and pharmacogenetic assays.",
keywords = "Juvenile rheumatoid arthritis, Pediatric inflammatory bowel disease, Personalized therapy, Pharmacodynamics, Pharmacogenetics, Pharmacokinetics",
author = "Gabriele Stocco and {de Iudicibus}, Sara and Raffaella Franca and Riccardo Addobbati and Giuliana Decorti",
year = "2012",
doi = "10.2174/138161212803530853",
language = "English",
volume = "18",
pages = "5766--5775",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "35",

}

TY - JOUR

T1 - Personalized therapies in pediatric inflammatory and autoimmune diseases

AU - Stocco, Gabriele

AU - de Iudicibus, Sara

AU - Franca, Raffaella

AU - Addobbati, Riccardo

AU - Decorti, Giuliana

PY - 2012

Y1 - 2012

N2 - Pediatric inflammatory and autoimmune diseases are a wide array of systemic or organ-specific conditions, characterized by an exaggerated immune reactivity, which generally occurs in immunogenetically predisposed children. Among the most important ones, in terms of their diffusion and morbidity in the population worldwide, pediatric inflammatory bowel disease (IBD) and juvenile rheumatoid arthritis (JRA) have to be considered. The aim of personalized therapy is to give to each patient the most appropriate drug and dose regimen, in order to maximize treatment response and reduce the risk of adverse events. In general, several therapeutic options exist for pediatric inflammatory and autoimmune conditions, therefore the perspective of pharmacological tools that allow identification of patients with increased risk of treatment issues related to a particular medication, in terms of lack of efficacy or increased probability of adverse events, is particularly desirable and promising. The present review will be focused on the personalized therapy approaches already available or in development for pediatric patients with IBD or JRA, comprising pharmacokinetic, pharmacodynamic and pharmacogenetic assays.

AB - Pediatric inflammatory and autoimmune diseases are a wide array of systemic or organ-specific conditions, characterized by an exaggerated immune reactivity, which generally occurs in immunogenetically predisposed children. Among the most important ones, in terms of their diffusion and morbidity in the population worldwide, pediatric inflammatory bowel disease (IBD) and juvenile rheumatoid arthritis (JRA) have to be considered. The aim of personalized therapy is to give to each patient the most appropriate drug and dose regimen, in order to maximize treatment response and reduce the risk of adverse events. In general, several therapeutic options exist for pediatric inflammatory and autoimmune conditions, therefore the perspective of pharmacological tools that allow identification of patients with increased risk of treatment issues related to a particular medication, in terms of lack of efficacy or increased probability of adverse events, is particularly desirable and promising. The present review will be focused on the personalized therapy approaches already available or in development for pediatric patients with IBD or JRA, comprising pharmacokinetic, pharmacodynamic and pharmacogenetic assays.

KW - Juvenile rheumatoid arthritis

KW - Pediatric inflammatory bowel disease

KW - Personalized therapy

KW - Pharmacodynamics

KW - Pharmacogenetics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84870229919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870229919&partnerID=8YFLogxK

U2 - 10.2174/138161212803530853

DO - 10.2174/138161212803530853

M3 - Article

C2 - 22726111

AN - SCOPUS:84870229919

VL - 18

SP - 5766

EP - 5775

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 35

ER -